Blog

“[…] we anticipate that heterogeneous persister populations are inevitable in [cancer] treatment.” Credit: 2023 Kim and Leung “[…] we anticipate that heterogeneous persister populations are inevitable in [cancer] treatment.” BUFFALO, NY- December 13, 2023 – A new editorial paper was published in Oncotarget’s Volume 14

“The extent of life extension achieved through this experimental study is the most effective achieved to date among other agents.” Credit: 2023 Ahn et al. “The extent of life extension achieved through this experimental study is the most effective achieved to date among other agents.”

(MEMPHIS, Tenn. – December 13, 2023) A study from St. Jude Children’s Research Hospital sheds light on the incidence of prediabetes and diabetes in childhood cancer survivors for better prevention and treatment. At a younger age, childhood cancer survivors can experience chronic conditions such as

PHILADELPHIA—(Dec. 13, 2023)—Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer. Led by Dr. Hildegund C.J. Ertl — a

Susan and Tandean Rustandy have donated $20 million to the University of Chicago Medicine to support development of Illinois’ first and only freestanding facility dedicated to cancer care and research, scheduled to open in 2027. Credit: UChicago Medicine Susan and Tandean Rustandy have donated $20

SAN FRANCISCO—December 13, 2023—In a study of historic scale, scientists at Gladstone Institutes have created an intricate map of how the immune system functions, examining the detailed molecular structures governing human T cells using the next-generation CRISPR tool known as base editing. Credit: Gladstone Institutes,

Patients with lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), often undergo progressive kidney damage, with approximately 20% of these patients advancing to end-stage renal disease. The current therapeutic landscape for LN, dominated by glucocorticoids and immunosuppressants, is limited by suboptimal response

Barcelona and Johannesburg, December 13th, 2023 Credit: Inbiomotion Barcelona and Johannesburg, December 13th, 2023 The Scientific Group, a leader in the IVD industry, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients have signed an agreement to

In the future, a little saliva may be enough to detect an incipient cancer. Researchers at the University of Gothenburg have developed an effective way to interpret the changes in sugar molecules that occur in cancer cells. Credit: Malin Arnesson In the future, a little

More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine